{"analyses":[{"ciLowerLimit":"10.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"37.8","estimateComment":"Mantel-Haenszel common risk difference was estimated by a normal approximation and Sato's variance estimator, stratified by rituximab-refractory status, number of prior lines of therapy, and geographic region.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0006","paramType":"Risk Difference (RD)","paramValue":"24.2","statisticalComment":"P-value was stratified by rituximab-refractory status, number of prior lines of therapy, and geographic region per interactive response technology.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.2","upperLimit":"53.9","value":"41.7"},{"groupId":"OG001","lowerLimit":"57.9","upperLimit":"73.8","value":"66.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) per the Lugano Classification for Non-Hodgkin's Lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"From first dose to primary analysis data cutoff (08OCT2021) start of a new anticancer therapy, or the crossover date, whichever came first. Median follow-up was 12.45 months.","title":"Overall Response Rate (ORR) as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}